| pubmed-article:17219031 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17219031 | lifeskim:mentions | umls-concept:C0026769 | lld:lifeskim |
| pubmed-article:17219031 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:17219031 | lifeskim:mentions | umls-concept:C0064636 | lld:lifeskim |
| pubmed-article:17219031 | lifeskim:mentions | umls-concept:C1545588 | lld:lifeskim |
| pubmed-article:17219031 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:17219031 | pubmed:dateCreated | 2007-1-12 | lld:pubmed |
| pubmed-article:17219031 | pubmed:abstractText | Axonal degeneration is a major cause of permanent disability in multiple sclerosis (MS). Recent observations from our and other laboratories suggest that sodium accumulation within compromised axons is a key, early step in the degenerative process, and hence that limiting axonal sodium influx may represent a mechanism for axonal protection in MS. Here we assess whether lamotrigine, a sodium channel-blocking agent, is effective in preventing axonal degeneration in an animal model of MS, namely chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE). When administered from 7 days post-inoculation, lamotrigine provided a small but significant reduction in the neurological deficit present at the termination of the experiments (averaged over three independent experiments; vehicle: 3.5+/-2.7; lamotrigine: 2.6+/-2.0, P<0.05) and preserved more functional axons in the spinal cord (measured as mean compound action potential area; vehicle: 31.7 microV.ms+/-23.0; lamotrigine: 42.9+/-27.4, P<0.05). Histological examination of the thoracic spinal cord (n=71) revealed that lamotrigine treatment also provided significant protection against axonal degeneration (percentage degeneration in dorsal column; vehicle: 33.5 %+/-38.5; lamotrigine: 10.4 %+/-12.5, P<0.01). The findings suggest that lamotrigine may provide a novel avenue for axonal protection in MS. | lld:pubmed |
| pubmed-article:17219031 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17219031 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17219031 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17219031 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17219031 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17219031 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17219031 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17219031 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17219031 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:17219031 | pubmed:issn | 0340-5354 | lld:pubmed |
| pubmed-article:17219031 | pubmed:author | pubmed-author:BerryDavidD | lld:pubmed |
| pubmed-article:17219031 | pubmed:author | pubmed-author:SunYueY | lld:pubmed |
| pubmed-article:17219031 | pubmed:author | pubmed-author:SmithKenneth... | lld:pubmed |
| pubmed-article:17219031 | pubmed:author | pubmed-author:KapoorRajuR | lld:pubmed |
| pubmed-article:17219031 | pubmed:author | pubmed-author:BechtoldDavid... | lld:pubmed |
| pubmed-article:17219031 | pubmed:author | pubmed-author:MillerSandra... | lld:pubmed |
| pubmed-article:17219031 | pubmed:author | pubmed-author:DawsonAngela... | lld:pubmed |
| pubmed-article:17219031 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17219031 | pubmed:volume | 253 | lld:pubmed |
| pubmed-article:17219031 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17219031 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17219031 | pubmed:pagination | 1542-51 | lld:pubmed |
| pubmed-article:17219031 | pubmed:dateRevised | 2011-11-3 | lld:pubmed |
| pubmed-article:17219031 | pubmed:meshHeading | pubmed-meshheading:17219031... | lld:pubmed |
| pubmed-article:17219031 | pubmed:meshHeading | pubmed-meshheading:17219031... | lld:pubmed |
| pubmed-article:17219031 | pubmed:meshHeading | pubmed-meshheading:17219031... | lld:pubmed |
| pubmed-article:17219031 | pubmed:meshHeading | pubmed-meshheading:17219031... | lld:pubmed |
| pubmed-article:17219031 | pubmed:meshHeading | pubmed-meshheading:17219031... | lld:pubmed |
| pubmed-article:17219031 | pubmed:meshHeading | pubmed-meshheading:17219031... | lld:pubmed |
| pubmed-article:17219031 | pubmed:meshHeading | pubmed-meshheading:17219031... | lld:pubmed |
| pubmed-article:17219031 | pubmed:meshHeading | pubmed-meshheading:17219031... | lld:pubmed |
| pubmed-article:17219031 | pubmed:meshHeading | pubmed-meshheading:17219031... | lld:pubmed |
| pubmed-article:17219031 | pubmed:meshHeading | pubmed-meshheading:17219031... | lld:pubmed |
| pubmed-article:17219031 | pubmed:meshHeading | pubmed-meshheading:17219031... | lld:pubmed |
| pubmed-article:17219031 | pubmed:meshHeading | pubmed-meshheading:17219031... | lld:pubmed |
| pubmed-article:17219031 | pubmed:meshHeading | pubmed-meshheading:17219031... | lld:pubmed |
| pubmed-article:17219031 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:17219031 | pubmed:articleTitle | Axonal protection achieved in a model of multiple sclerosis using lamotrigine. | lld:pubmed |
| pubmed-article:17219031 | pubmed:affiliation | Department of Clinical Neuroscience, King's College London, Guy's Campus, National Hospital for Neurology and Neurosurgery, London, UK. | lld:pubmed |
| pubmed-article:17219031 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17219031 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17219031 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17219031 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17219031 | lld:pubmed |
